ORP-101 in Irritable Bowel Syndrome with Diarrhea: A Phase II Randomized, Controlled Trial

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Peppermint oil and sweets in pediatric irritable bowel syndrome and functional abdominal pain: a randomized trial

Clin Gastroenterol Hepatol

Vermeijden NK, van der Feen C, Groeneweg M, Hummel T, Zagers D, Bertrams-Maartens I, van Wering H, Hurkmans P, Stapelbroek J, Sauvé I, Wessels M, Teklenburg-Roord S, Pruijsen-Nienhuis JM, Theuns-Valks SDM, Plomp TC, Bunkers C, Keszthelyi D, Benninga MA, Vlieger AM

doi: 10.1016/j.cgh.2026.01.014

Inflammatory Bowel Disease

A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial

BMC Gastroenterol

Tack C, Van den Houte K, Besard L, Capiau L, Ceulemans S, Gernay O, Maes S, Peetermans C, Raat W, Stubbe J, Van Boxstael R, Vandeput O, Van Steenbergen S, Gehesquière B, Raes J, Tack J, Carbone F

doi: 10.1186/s12876-025-04494-7

Gastrointestinal Cancer

Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)

Eur J Cancer

Tashiro K, Osumi H, Kataoka K, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Suwa Y, Mizusawa J, Sano Y, Suto T, Murata K, Adachi T, Ueno H, Ikeda S, Komori K, Shiozawa M, Tsukamoto S, Takashima A, Kanemitsu Y

doi: 10.1016/j.ejca.2026.116957

Colonoscopy

The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease

BMC Gastroenterol

Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, Murthy SK, Hoentjen F

doi: 10.1186/s12876-026-05046-3

Gastritis

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators

doi: 10.1016/S2468-1253(26)00116-0

Irritable Bowel Syndrome (IBS) and Chronic ConstipationInflammatory Bowel Disease

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease with Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus

Gastroenterology

Ma C, Ford AC, Hashash JG, Barbara G, Bernstein CN, Brenner DM, Griffiths AM, Keefer L, Long MD, Nurko S, Singh P, Sands BE, Chang L

doi: 10.1053/j.gastro.2026.04.008

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

Lancet Gastroenterol Hepatol

Thakur ER, Khasawneh M, Moayyedi P, Black CJ, Ford AC

doi: 10.1016/S2468-1253(25)00238-9

Gastrointestinal Cancer

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial

Lancet Oncol

Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, West N, Quirke P, Sun Myint A, Bach S, Parsons P, Dhadda AS, Brown N, Brown G, Harrison M, Maggs R, Begum R, Chang E, Hackshaw A, Lopes A, ARISTOTLE Trial Management Group and Investigators

doi: 10.1016/S1470-2045(26)00132-4

Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Lancet Gastroenterol Hepatol

Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL

doi: 10.1016/S2468-1253(26)00123-8

Related content

Peppermint oil and sweets in pediatric irritable bowel syndrome and functional abdominal pain: a randomized trial

A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial

Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)

The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease with Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus

Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial